• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRAF 突变与原发性黑色素瘤临床病理特征的荟萃分析

Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.

机构信息

Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea.

Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Seoul, Korea.

出版信息

J Am Acad Dermatol. 2015 Jun;72(6):1036-46.e2. doi: 10.1016/j.jaad.2015.02.1113. Epub 2015 Mar 25.

DOI:10.1016/j.jaad.2015.02.1113
PMID:25819940
Abstract

BACKGROUND

BRAF mutations occur in some melanomas. We hypothesized that BRAF mutation rates may differ in melanomas found in Asian compared to white populations.

OBJECTIVE

We performed a metaanalysis of BRAF mutations and their associations with the clinicopathologic characteristics of primary melanoma (PM), with a subgroup analysis to compare Asian and white patients with PM.

METHODS

The PubMed, EMBASE, and Cochrane databases were searched up to November 2013. The incidence rates and odds ratios (ORs) of BRAF mutations were calculated using a fixed or random effects model.

RESULTS

BRAF mutation was associated with younger age (OR = 1.734; P < .001), trunk location (OR = 2.272; P < .001), non-chronically sun damaged skin (OR = 2.833; P < .001), superficial spreading melanoma (OR = 2.081; P < .001), and advanced melanoma stage (OR = 1.551; P = .003). The incidence of BRAF mutations in Asian patients with PM was half that of white patients with PM, but it was linked to the same clinicopathologic characteristics.

LIMITATIONS

Only a small number of studies have been conducted on Asian patients with PMs.

CONCLUSIONS

The BRAF mutation in PM was associated with age, anatomic site based on ultraviolet radiation exposure, histologic subtype, and advanced stage of melanoma. The clinicopathologic associations with BRAF mutations were similar in Asian and white patients with PM.

摘要

背景

BRAF 突变发生于一些黑色素瘤中。我们推测,亚洲人群与白人人群黑色素瘤中的 BRAF 突变率可能存在差异。

目的

我们进行了 BRAF 突变与原发性黑色素瘤(PM)临床病理特征相关性的荟萃分析,并进行了亚组分析以比较亚洲人和白人 PM 患者。

方法

检索了 PubMed、EMBASE 和 Cochrane 数据库,检索时间截至 2013 年 11 月。采用固定或随机效应模型计算 BRAF 突变的发生率和比值比(OR)。

结果

BRAF 突变与年龄较小(OR=1.734;P<0.001)、躯干位置(OR=2.272;P<0.001)、非慢性日光损伤皮肤(OR=2.833;P<0.001)、浅表扩散性黑色素瘤(OR=2.081;P<0.001)和晚期黑色素瘤分期(OR=1.551;P=0.003)相关。亚洲 PM 患者 BRAF 突变的发生率为白人 PM 患者的一半,但与相同的临床病理特征相关。

局限性

仅有少数研究涉及亚洲 PM 患者。

结论

PM 中的 BRAF 突变与年龄、紫外线辐射暴露部位、组织学亚型和黑色素瘤的晚期有关。亚洲人和白人 PM 患者中 BRAF 突变与临床病理特征的相关性相似。

相似文献

1
Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma.BRAF 突变与原发性黑色素瘤临床病理特征的荟萃分析
J Am Acad Dermatol. 2015 Jun;72(6):1036-46.e2. doi: 10.1016/j.jaad.2015.02.1113. Epub 2015 Mar 25.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.免疫组织化学作为检测黑色素瘤中BRAF-V600E突变的可靠方法:对当前已发表文献的系统评价和荟萃分析
J Surg Res. 2016 Jun 15;203(2):407-15. doi: 10.1016/j.jss.2016.04.029. Epub 2016 Apr 23.
4
Incidence, stage and outcome of malignant melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks?白癜风或斑秃患者中恶性黑色素瘤、角质形成细胞癌及其他癌症的发病率、分期和预后:个体内或家族性风险?
Br J Dermatol. 2025 Jun 20;193(1):66-73. doi: 10.1093/bjd/ljaf074.
5
Melanoma skin cancer statistics derived from 7442 Japanese patients: Japanese melanoma study.来自7442名日本患者的皮肤黑色素瘤统计数据:日本黑色素瘤研究
Int J Clin Oncol. 2025 May;30(5):844-855. doi: 10.1007/s10147-025-02747-9. Epub 2025 Apr 7.
6
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.BRAF/MEK 靶向治疗改善了随机临床试验中 BRAF 突变型黑色素瘤女性患者的结局:系统评价和荟萃分析。
Semin Oncol. 2023 Feb-Apr;50(1-2):34-39. doi: 10.1053/j.seminoncol.2023.03.003. Epub 2023 Mar 21.
7
Neoadjuvant treatment for stage III and IV cutaneous melanoma.新辅助治疗 III 期和 IV 期皮肤黑色素瘤。
Cochrane Database Syst Rev. 2023 Jan 17;1(1):CD012974. doi: 10.1002/14651858.CD012974.pub2.
8
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.前哨淋巴结活检后行局部原发性皮肤黑色素瘤淋巴结清扫术。
Cochrane Database Syst Rev. 2015 May 16;2015(5):CD010307. doi: 10.1002/14651858.CD010307.pub2.
9
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.未经治疗的晚期 BRAF 突变型黑色素瘤的系统治疗:随机临床试验的系统评价和网络荟萃分析。
JAMA Oncol. 2017 Mar 1;3(3):366-373. doi: 10.1001/jamaoncol.2016.4877.
10
Clinical, dermatoscopic, histological and molecular predictive factors of distant melanoma metastasis: A systematic review and meta-analysis.临床、皮肤镜、组织学和分子预测因素对黑色素瘤远处转移的影响:系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2024 Oct;202:104458. doi: 10.1016/j.critrevonc.2024.104458. Epub 2024 Jul 27.

引用本文的文献

1
Real-World Outcomes of Pembrolizumab in Advanced Melanoma by Age and Sex: A National Population-Based Study.帕博利珠单抗治疗晚期黑色素瘤的年龄和性别相关真实世界结局:一项基于全国人口的研究。
Target Oncol. 2025 Jun 30. doi: 10.1007/s11523-025-01164-2.
2
Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours.中国恶性黑色素瘤合并其他原发性肿瘤患者的临床特征、预后及基因突变差异。
Ann Med. 2025 Dec;57(1):2493769. doi: 10.1080/07853890.2025.2493769. Epub 2025 May 3.
3
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
巨细胞病毒血清学状态与抗程序性死亡蛋白1(PD-1)检查点阻断治疗后生存率提高及毒性发作延迟相关。
Nat Med. 2025 Apr 23. doi: 10.1038/s41591-025-03647-1.
4
Predicting Mutations in Cutaneous Melanoma Patients Using Neural Network Analysis.使用神经网络分析预测皮肤黑色素瘤患者的突变
J Skin Cancer. 2024 Dec 19;2024:3690228. doi: 10.1155/jskc/3690228. eCollection 2024.
5
BRAF and NRAS Mutations and the Association with Prognosis of Acral Lentiginous and Nodular Melanomas in Indonesia.BRAF 和 NRAS 突变与印度尼西亚肢端雀斑样和结节性黑色素瘤预后的关系。
Asian Pac J Cancer Prev. 2024 Oct 1;25(10):3525-3531. doi: 10.31557/APJCP.2024.25.10.3525.
6
Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review.成釉细胞瘤的抗丝裂原活化蛋白激酶靶向治疗:病例报告及系统评价
Cancers (Basel). 2024 Jun 7;16(12):2174. doi: 10.3390/cancers16122174.
7
BRAF V600E Mutation in Malignant Melanoma-A Romanian Research Experience.恶性黑色素瘤中的 BRAF V600E 突变——罗马尼亚的一项研究经验。
Medicina (Kaunas). 2024 Feb 20;60(3):351. doi: 10.3390/medicina60030351.
8
Recent advancements in the diagnosis and treatment of acral melanoma.肢端黑色素瘤的诊断和治疗新进展。
J Zhejiang Univ Sci B. 2024 Feb 15;25(2):106-122. doi: 10.1631/jzus.B2300221.
9
Incidence of mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population.皮肤黑色素瘤中突变的发生率:乌克兰人群的组织病理学和分子分析
Melanoma Manag. 2023 Dec 21;10(1):MMT64. doi: 10.2217/mmt-2023-0005. eCollection 2023 Mar.
10
Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib.达拉非尼/曲美替尼治疗BRAF-ZKSCAN5融合基因黑色素瘤病例的疗效
Case Rep Oncol. 2023 Sep 22;16(1):1007-1012. doi: 10.1159/000533822. eCollection 2023 Jan-Dec.